BGT
BIOGENETEC FPO [BGT]
Healthcare · ASX Small Cap
$0.0350 +0.0%
Updated 26 Mar 2026 · Scores refresh every scan
Score Breakdown
Technical68
Catalyst51
Sentiment50
Fundamental41
Momentum80
Risk Gate34
Get alerts when BGT's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Active Signals
Bullish Signals
- Stochastic is deep in oversold territory — bounce conditions forming
- Beating the Small Ords index — relative strength of 1.15, so it's outpacing the pack
- Trading above the 200-day average — the long-term trend is on your side
- Critical cash runway (1.7 quarters)
- Strong revenue growth (+208%)
- Micro-cap ($5-20M) - high risk
- CANSLIM S: Tight float (35%)
- Sentiment is mixed — no strong consensus either way
- Strong long-term momentum — up 55% over the past year (excluding last month)
- Revenue growing at +208% — the top line is moving in the right direction
- The bigger volume days are the up days — volume-weighted momentum is positive (5.88%/day)
- Altman Z-Score distress zone (1.15 < 1.81, low-confidence approx)
- Low-priced stock risk ($0.035)
- RBA hiking (-3pts)
Risk Signals
- Not enough chatter to gauge sentiment — defaulting to neutral
- Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about BGT
3 free messages/day · Unlimited with Pro
Recent Catalysts
LOW Bio-Gene to present at NWR Healthcare Conference
NONE Sumitomo & Nakashima to launch Qcide products in Japan
NONE Update on Qcide Production
NONE Regulatory Development of Flavocide
Recent ASX Announcements
| 2026-03-19 | Bio-Gene to present at NWR Healthcare Conference |
| 2026-03-15 | Sumitomo & Nakashima to launch Qcide products in Japan PRICE SENSITIVE |
| 2026-03-09 | Update on Qcide Production |
| 2026-03-02 | Regulatory Development of Flavocide PRICE SENSITIVE |
| 2026-02-23 | Appendix 4D and Half-Year Accounts 31 December 2025 PRICE SENSITIVE |
Key Metrics
$10.7M
Market Cap
128K
Avg Volume
1.5x
Vol Ratio
$0.02 — $0.06
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-202.2%
ROE
N/A
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | pass | Float: 35% |
| L | Leader vs Laggard | pass | RS: 12 |
| I | Institutional Sponsorship | insufficient_data | Inst: 0% |
| M | Market Direction | neutral | Neutral |
Sector: Healthcare
Ranked #13 of 117 · Sector avg: 46
View all Healthcare signals →Track BGT and 2,200+ ASX stocks
Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.
No credit card required